Natick-Based Allurion Gets Approval To Launch Gastric Balloon Technology in Brazil

In the full sense, the following press release & photo is submitted to SOURCE media via commercial telephone service.


NATICK – Allurion, a company dedicated to ending obesity, has received approval to launch revolutionary gastric balloon technology in Brazil.

Also Read :  Today in the Connected Economy: Snap's AR Fashion

The Allurion Balloon – known in Brazil as the Elipse Balloon – is the first abdominal weight loss balloon that is routinely placed and removed without surgery, endoscopy or anesthesia.1. With its launch in Brazil, Allurion Balloon is now available in 60 countries.

Also Read :  Online platform with Sonoma County connection Hello Alice helps business owners launch for success

The obesity rate in Brazil has increased from 11.8% in 2006 to 20.3% in 2019.

By 2030, nearly 30% of Brazilian adults will be obese.

As a result, Allurion estimates a total addressable market of approximately 1.3 million consumers in Brazil who would be eligible and would consider choosing the Allurion Program.

Dr. Shantanu Gaur, Co-founder and CEO of Allurion, said the need to address obesity in Brazil is more urgent than ever.

“Obesity represents one of the biggest health challenges in Brazil today (Friday, October 28). We welcome ANVISA’s approval, and look forward to working with health professionals and other weight loss professionals to end obesity in the country.”

Benoit Chardon, Chief Marketing Officer at Allurion, said the approval is the company’s latest move into markets where obesity is a serious health challenge.

“We are confident of our future success in Brazil, because we have three main advantages: the revolution, the nature of our device, the complete nature of our program which includes a patient monitoring system with distance with the power of AI and behavior change program that is compatible with the device, and the experience we have gathered after treating more than 100,000 patients around the world,” he said.

The Allurion program is available in 5 hospitals in Brazil, with 7 more to open soon. As with other businesses, Chardon said Allurion will be selective in initially partnering with hospitals to offer the program. “We want to ensure the best experience for all our patients: only the most experienced organizations and hospitals will be trained to deliver this innovative program,” he said.

The company has demonstrated strong market-relevance in more than 50 countries to date and has grown its revenue by 100% year-over-year for the past 6 years. With launches this year in Australia, Canada, Mexico, India, and now Brazil, the company has nearly doubled its footprint in the past 12 months.

Dr. Eduardo Grecco, a gastroenterologist and endoscopy surgeon at the Instituto Endovitta in São Paulo, Brazil, welcomed more tools to help fight obesity.

“According to the Secretariat De Vigilância em Saúde, the local health agency, about 20% of the adult population currently lives with obesity and a further 36% are obese. This is about 95 million people, ” he said.

“We’ve seen an 80 per cent increase in obesity in the last 10 years – particularly among 25- to 45-year-olds. This has implications for other conditions where obesity is a major risk factor.”

Dr. Manoel Galvao Neto, head of bariatric research at Mohak Bariatric and Robotics and scientific director at Instituto Endovitta, agrees. “It’s important that we act now to help these people lose weight. Having a tool like the Allurion Program in our hands will be a game changer.”

About Allurion Balloon (marketed as Elipse Balloon in Brazil)

  • The Allurion swallowable stomach balloon is the world’s first non-invasive weight loss device. It does not require surgery, endoscopy or anesthesia for routine placement or removal1. In Brazil, it is indicated for adults with a body mass index (BMI) of 30-40
  • It comes as part of the Allurion Program, which supports patients to make healthy lifestyle changes that lead to long-term weight loss. The comprehensive program includes support from a doctor and nutritionist, as well as a collection of digital tools designed to help increase success.
  • The Allurion program is designed for people who cannot achieve their weight loss goals through diet alone, and who do not want – or cannot – undergo surgery or endoscopy. It may also be suitable for people who need to manage weight-related diseases, such as diabetes, infertility, or heart disease.

* Total market opportunity calculation is based on current health statistics, income levels and company market penetration

** Estivaleti, JM, Guzman-Habinger, J., Lobos, J. and al. Time trends and projections of obesity in Brazilian adults between 2006 and 2030. Sci Rep 12, 12699 (2022).

1 In rare cases, the Allurion Balloon may require endoscopic or surgical removal

Allurion is dedicated to ending obesity. The Allurion program is a 360-degree weight loss experience featuring the Allurion Gastric Balloon, the world’s first and only swallowable, non-invasive device.1 internal balloon for weight loss, Allurion Virtual Care Suite including Allurion Mobile App for consumers, Allurion Insights for doctors featuring Iris AI Platform, and Allurion Connected Scale and Health Tracker. Allurion VCS is now available to providers separately from the Allurion Program to help customize, monitor and manage weight loss treatment for patients regardless of treatment plan: gastric balloon, surgery, medical or nutritional. The company is headquartered in Natick.


Leave a Reply

Your email address will not be published.